News for ACST Stock

Acasti Announces Corporate Name Change to Grace Therapeutics, Inc. Acasti Announces Completion of Patient Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104 Acasti to Present at the Life Sciences Investor Forum Acasti to Participate in the H.C. Wainwright 26th Annual Global Investment Conference Acasti Announces First Fiscal Quarter 2025 Financial Results, Provides Business Update Acasti Announces Achievement of 50% Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial Acasti Announces Year-End 2024 Financial Results, Provides Business Update Acasti Pharma to Attend BIO International Convention 2024 Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights Acasti Announces Poster Detailing its GTX-104 STRIVE-ON Trial Acasti to Participate in Upcoming San Francisco Investor Conferences in January 2024 Acasti Announces Second Quarter 2024 Financial Results and Business Highlights Acasti Announces Dosing of First Patient in GTX-104 STRIVE-ON Trial Acasti Pharma to Host KOL Event on GTX-104: A Potential New Treatment Standard for Rare and Life-Threatening aneurysmal Subarachnoid Hemorrhage (aSAH) Acasti Announces $7.5 Million Private Placement Equity Financing Acasti to Participate in the H.C. Wainwright Global Investment Conference Acasti Announces First Quarter 2024 Financial Results and Business Highlights Acasti to Present GTX-104 Pharmacokinetic Comparison Data at Neurocritical Care Annual Meeting Acasti Announces WuXi Clinical as CRO to Conduct STRIVE-ON Pivotal Phase 3 Safety Trial for GTX-104 in aSAH Patients Acasti Pharma Announces 1-for-6 Reverse Stock Split Acasti Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol and Confirms Planned Initiation of STRIVE-ON in aSAH Patients in Calendar Q4 2023 Acasti Pharma Reports Fiscal Year 2023 Operational Results Acasti Announces Appointment of New Scientific Advisory Board Members Acasti to Participate in the Lytham Partners Spring 2023 Investor Conference Acasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash Runway Through Calendar Q2 2025 Acasti to Proceed with Phase 3 Clinical Safety Study for GTX-104 Following FDA Feedback, and Upon Approval of the Full Study Protocol to be Submitted to the IND Acasti Announces Appointment of Prashant Kohli as CEO Acasti Pharma Inc. Announces the Resignation of a Director Acasti Pharma Inc. Centralizes Marketplace for Shares on the Nasdaq with Voluntary Delisting from TSX Venture Exchange Acasti Pharma to Participate in Oppenheimer 33rd Annual Healthcare Conference Acasti Pharma Recognizes Rare Disease Day Acasti Pharma Reports Third Quarter 2023 Operational Results Acasti Pharma to Report Third Quarter 2023 Financial Results on Tuesday, February 14, 2023 Acasti Receives Extension to Regain Compliance with NASDAQ Minimum Bid Price Rule Acasti Pharma to Present at Lytham Partners Investor Select Conference on January 31 Acasti Pharma to Present at Sidoti Virtual Investor Conference on January 18 Acasti to Host Conference Call on Tuesday, January 10, 2023 to Discuss Results from Recent Phase 1 PK Studies for GTX-101 and GTX-102 That Met All Outcome Measures Acasti Announces Preliminary Topline Results Met All Outcome Measures in the Pharmacokinetic Bridging Study for GTX-102, the Company’s Drug Candidate for the Treatment of Ataxia Telangiectasia Acasti Pharma Announces Preliminary Topline Results Met All Primary Outcome Measures in the Single Dose Pharmacokinetic Study for GTX-101, the Company’s Drug Candidate for the Treatment of Postherpetic Neuralgia (PHN) Acasti Pharma Reports Second Quarter 2023 Operational Results Acasti Pharma to Present at Q4 Investor Summit Acasti Pharma to Report Second Quarter 2023 Financial Results on Monday, November 14, 2022 Acasti Announces Court Dismissal of Stockholder Litigation Acasti Announces Voting Results from 2022 Annual and Special Meeting of Shareholders Acasti Pharma to Participate in the Lytham Partners Fall 2022 Investor Conference Acasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-102, the Company’s Drug Candidate for the Treatment of Ataxia Telangiectasia Acasti Pharma to Participate at the H.C. Wainwright 24th Annual Global Investment Conference Acasti Pharma Reports First Quarter 2023 Operational Results Acasti Pharma to Report First Quarter 2023 Financial Results on Thursday, August 11, 2022 Acasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-101, the Company’s Drug Candidate for the Treatment of Postherpetic Neuralgia Acasti Pharma Announces Annual Grants of Performance Stock Options Acasti Pharma Reports Fiscal Year 2022 Operational Results Acasti Pharma Schedules Fiscal Year 2022 Business Update Conference Call Acasti Pharma Announces the Issuance of Additional Patents for GTX-104 and GTX-101 Acasti Pharma Inc. Retains Lytham Partners to Lead Strategic Investor Relations and Shareholder Communication Program Acasti Pharma Announces Positive Results for Pharmacokinetic Bridging Study, With Intravenous GTX-104 Meeting All Endpoints Update: Acasti Pharma CEO to Present at Microcap Rodeo’s Spring into Action Best Ideas Virtual Conference on May 18th Acasti Pharma CEO to Present at Microcap Rodeo's Spring into Action Best Ideas Virtual Conference on May 16th Acasti Pharma to Present at the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference on April 28th Acasti Pharma Appoints Healthcare Industry Leader Michael L. Derby to its Board of Directors Acasti Pharma Announces Patents for GTX-104 in Europe, GTX-102 in the U.S. and GTX-101 in Japan Acasti Pharma CEO to Present at the 32nd Annual Oppenheimer Healthcare Conference on March 16th Acasti Pharma Celebrates Rare Disease Day Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2022 Acasti Pharma Schedules Third Quarter Fiscal 2022 Business Update Conference Call Acasti Pharma to Present at the H.C. Wainwright BioConnect 2022 Conference Acasti Pharma Announces Interim Data Meets All Primary Endpoints for Pivotal PK Study for GTX-104 Acasti Pharma CEO to Participate in the Benzinga All Access Event on December 2nd Acasti Pharma Announces Annual Stock Option Grants Acasti Pharma Provides Business Update for the Second Quarter of Fiscal 2022 Acasti Pharma Schedules Second Quarter Fiscal 2022 Business Update Conference Call Acasti Pharma Awarded Composition-of-Matter Patents for GTX-101 in Europe, China and Mexico and for GTX-102 in Japan Acasti Pharma Announces Initiation of Pharmacokinetic Bridging Study for GTX-104, the Company’s Lead Drug Candidate for the Treatment of Subarachnoid Hemorrhage Acasti Pharma Provides Update Following Acquisition of Grace Therapeutics and Regains Compliance with Nasdaq Listing Standards Acasti Pharma to Present at the Oppenheimer Fall Healthcare Summit on September 21ˢᵗ Acasti Pharma to Present at the H.C. Wainwright 23rd Annual Global Investment Conference Acasti Pharma Announces Successful Completion of its Merger with Grace Therapeutics, Inc., Voting Results of its Annual and Special Meeting of Shareholders and Reverse Stock Split Acasti Pharma Provides Business Update for the First Quarter of Fiscal 2022 Reminder: Acasti Pharma to Host Conference Call on August 4th at 1:00 PM ET to Discuss Planned Acquisition of Grace Therapeutics Acasti Pharma Schedules Conference Call for August 4th at 1:00 PM ET to Discuss Planned Acquisition of Grace Therapeutics Acasti Pharma Provides Fiscal 2021 Year-End Business Update Acasti Intends to Request Hearing Before Nasdaq Panel to Present Plan of Compliance Acasti Announces Definitive Agreement to Acquire Grace Therapeutics, Inc. Acasti Pharma Provides Update on Recent Financing Activities Acasti Pharma Announces Results for Third Quarter of Fiscal 2021 Acasti Pharma Announces the Election of Its Directors, Advisory Resolution Approving Compensation, Amendments to Its Stock Option and Equity Incentive Plans, Adoption of Amended & Restated General By-Law and Other Related Matters Approved at Its AGM Acasti Announces Review Process of Strategic Alternatives Acasti Appoints Seasoned Executive Brian D. Ford CPA-CA as Chief Financial Officer Acasti Announces Filing and Mailing of Information Circular and Change in Record Date Acasti Pharma Reports Topline Triglyceride Results from Phase 3 TRILOGY 2 Study of CaPre in Patients with Severe Hypertriglyceridemia